Table 3. Crude and adjusted hazard ratios for the association between the use of contaminated ranitidine with all-cause mortality in the propensity score-matched cohort (n = 55,584)

	Event	N (%)	Events	Person-years	Event incidence rate*	HR (95% CI)§
Secondary analysis: All-cause mortality events
No exposure	All-cause mortality	27,792	1,758	173,511	10.1	1.00 (reference)
Exposure	All-cause mortality	27,792	1,933	171,722	11.3	1.04 (0.97 to 1.11)
Cumulative exposure (mg)
<70,000	All-cause mortality	9,901	590	60,786	9.7	1.06 (0.97 to 1.17)
70,000-129,999	All-cause mortality	9,098	636	56,329	11.3	1.06 (0.97 to 1.16)
≥130,000	All-cause mortality	8,793	707	54,606	12.9	1.00 (0.91 to 1.09)
P for trend						0.424
Cumulative duration of use (years)
<1	All-cause mortality	14,391	875	88,786	9.9	1.06 (0.98 to 1.15)
1-2	All-cause mortality	7,670	592	47,339	12.5	1.08 (0.98 to 1.18)
≥2	All-cause mortality	5,731	466	35,597	13.1	0.95 (0.86 to 1.05)
P for trend						0.117

Abbreviations here: CI, confidence interval; H2 blocker, histamine H2 receptor antagonist; HR, hazard ratio; NDMA, N-nitrosodimethylamine; SD, standard deviation.
Cancer incidence rate is expressed as per 1,000 person-years.
Risk factors were adjusted for age; sex; frequency of alcohol consumption; region of residence (rural or urban); body mass index (<25, 25–30, or ≥30 kg/m²); systolic blood pressure, diastolic blood pressure, fasting blood glucose, and serum total cholesterol (continuous variables); history of diabetes mellitus, stroke, or hypertension; Charlson comorbidity index (0-1, 2, or ≥3), alcoholic drinks (<1, 1-2, 3-4, or ≥5 days per week); household income (low, middle, or high), smoking (never smoker, ex-smoker, or current smoker); physical activity (0, 1–2, 3–4, 5–6, or 7 sessions per week); and use of a proton pump inhibitor, statin, systemic glucocorticoid, metformin, aspirin, or hormone replacement therapy.
Number in bold indicate significant differences (P < 0.05).